On September 3, 2007 Vernalis plc reported the achievement of a milestone under the company’s joint research and development collaboration with Novartis on the oncology target Hsp90 (Press release, Cancer Research Technology, SEP 3, 2007, View Source [SID1234523385]). The milestone payment was triggered by the start of Phase I clinical trials of a Vernalis compound in a range of solid tumours and liquid cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Vernalis Hsp90 programme is the result of a collaboration established in March 2002 with CRT and The Institute of Cancer Research, building on studies funded by The ICR, Cancer Research UK and Wellcome Trust. Under the agreement, Vernalis will pay CRT and The ICR a proportion of its revenues from the agreement with Novartis. The original press release from Vernalis can be viewed here.